Radiotherapy combined with hormonal therapy in prostate cancer: the state of the art

References

• JemalASiegelRWardECancer statistics, 2009CA Cancer J Clin20095922524919474385
   PubMed Web of Science ®Google Scholar
• SharifiNGulleyJLDahutWLAndrogen deprivation therapy for prostate cancerJAMA200529423824416014598
   PubMed Web of Science ®Google Scholar
• WidmarkAKleppOKolbergAEndocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): and open randomized phase III trialLancet200937330130819091394
   PubMed Web of Science ®Google Scholar
• MileckiPKwiasZHormonal therapy combined with radiotherapy in locally advanced prostate cancerRep Pract Oncol Radiother20027157163
   Google Scholar
• ShelleyMDKumarSColesBWiltTStaffurthJMasonMDAdjuvant hormone therapy for localised and locally advanced prostate carcinoma: a systematic review and meta-analysis of randomised trialsCancer Treat Rev20093554054619493624
   PubMed Web of Science ®Google Scholar
• CooperbergMRGrossfeldGDLubeckDPCarrollPRNational practice patterns and time trends in androgen ablation for localized prostate cancerJ Natl Cancer Inst20039598198912837834
   PubMedGoogle Scholar
• ShahinianVBKuoYFreemanJLOrihuelaEGoodwinJSIncreasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinomaCancer20051031615162415742331
   PubMed Web of Science ®Google Scholar
• ShahinianVBKuoYFFreemanJLGoodwinJSRisk of the “androgen deprivation syndrome” in men receiving androgen deprivation for prostate cancerArch Intern Med200616646547116505268
   PubMed Web of Science ®Google Scholar
• GuiseTAOefeleinMGEasthamJACooksonMSHiganoCSSmithMREstrogenic side effects of androgen deprivation therapyRev Urol2007916318018231613
   PubMedGoogle Scholar
• HugginsCHodgesCStudies on prostatic cancer: the effect of castration, of estrogen, and androgen injection on serum phosphatases in metastatic carcinoma of the prostateCancer Res19411293297
   Google Scholar
• ChenYCleggNJScherHIAnti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established targetLancet Oncol20091098199119796750
   PubMed Web of Science ®Google Scholar
• EdwardsJKrishnaNSGrigorKMBartlettJMAndrogen receptor gene amplification and protein expression in hormone refractory prostate cancerBr J Cancer20038955255612888829
   PubMed Web of Science ®Google Scholar
• TitusMASchellMJLihFBTomerKBMohlerJLTestosterone and dihydrotestosterone tissue levels in recurrent prostate cancerClin. Cancer Res2005114653465716000557
   PubMed Web of Science ®Google Scholar
• SolowayMSharifiRWajsmanZMcLeodDWoodDPJrPuras-BaezARandomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancerJ Urol19951544244287541859
   PubMed Web of Science ®Google Scholar
• AusGAbrahamssonPAAhlrenGHormonal treatment before radical prostatectomy: a 3-year follow-upJ Urol199815920162017
   Web of Science ®Google Scholar
• ZietmanALPrinceEANakfoorBMParkJJAndrogen deprivation and radiation therapy: sequencing studies using the Shionogi in vivo tumor systemInt J Radiat Oncol Biol Phys199738106710709276373
   PubMed Web of Science ®Google Scholar
• McconnellJDPhysiologic basis of endocrine therapy for prostatic cancerUrol Clin North Am199118171899494
   PubMed Web of Science ®Google Scholar
• KaminskiJMHanlonALJoonDLMeistrichMHachemPPollackAEffect of sequencing of androgen deprivation and radiotherapy on prostate cancer growthInt J Radiat Oncol Biol Phys200357242812909211
   PubMed Web of Science ®Google Scholar
• ZelefskyMJHarrisonANeoadjuvant androgen ablation prior to radiotherapy for prostate cancer: reducing the potential morbidity of therapyUrology199749Suppl 3 A38459123735
   PubMed Web of Science ®Google Scholar
• MarcenaroMSanguinetiGFranzonePNeoadjuvant androgen deprivation and prostate gland shrinkage during conformal radiotherapyInt J Radiat Oncol Biol Phys200151ASTRO1819
   Google Scholar
• MovsasBChapmanJDHorwitzEMHypoxic regions exist in human prostate carcinomaUrology19995311189886581
   PubMed Web of Science ®Google Scholar
• IsaacsJTLundmoPIBergesRMartikainenPKyprianouNEnglishHFAndrogen regulation of programmed death of normal and malignant prostatic cellsJ Androl1992134574641293127
   PubMed Web of Science ®Google Scholar
• RodenACMoserMTTriSDAugmentation of T cell levels and responses induced by androgen deprivationJ Immunol20041736098610815528346
   PubMed Web of Science ®Google Scholar
• Lu-YaoGLAlbertsenPCMooreDFSurvival following primary androgen deprivation therapy among men with localized prostate cancerJAMA200830017318118612114
   PubMed Web of Science ®Google Scholar
• ASTRO 2009, in November 2009 [ASTRO abstract]. RTOG 94–08.
   Google Scholar
• BollaMColletteLBlankLLong-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trialLancet200236010310612126818
   PubMed Web of Science ®Google Scholar
• D’AmicoAVSchultzDLoffredoMBiochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancerJAMA20002841280128310979115
   PubMed Web of Science ®Google Scholar
• CiezkiJPKleinEAAngermeierKA retrospective comparison of androgen deprivation (AD) vs no AD among low-risk and intermediate-risk prostate cancer patients treated with brachytherapy, external beam radiotherapy, or radical prostatectomyInt J Radiat Biol Phys20046013471350
   Web of Science ®Google Scholar
• 2010 Genitourinary Cancers Symposium (GUCS)San Francisco Abstract 62010 Mar 5
   Google Scholar
• D’AmicoAVManolaJLoffredoM6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trialJAMA200429282182715315996
   PubMed Web of Science ®Google Scholar
• D’AmicoAVChenMHRenshawAALoffredoMKantoffPWAndrogen suppression and radiation vs radiation alone for prostate cncer: a randomized trialJAMA200829928929518212313
   PubMed Web of Science ®Google Scholar
• DenhamJWSteiglerALambDSShort-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trialLancet Oncol2005684185016257791
   PubMed Web of Science ®Google Scholar
• Radiation Theory Oncology GroupRTOG 99-10. A Phase III trial to evaluate the duration of neoadjuvant total androgen suppression (TAS) and radiation therapy (RT) in intermediate-risk prostate cancer Available from http://www.rtog.org/members/protocols/99-10/99-10.pdf. Accessed 2010 September 27.
   Google Scholar
• Radiation Theory Oncology GroupRTOG 08-15. A Phase III prospective randomized trial of dose-escalated radiotherapy with or without short-term androgen deprivation therapy for patients with intermediate risk prostate cancer Available from http://www.rtog.org/members/protocols/0815/0815.pdf. Accessed 2010 September 27.
   Google Scholar
• PilepichMVCaplanRByhardtRWPhase III trial of androgen supression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Oncology Group Protocol 85-31J Clin Oncol199715101310219060541
   PubMed Web of Science ®Google Scholar
• LawtonCAWinterKMurrayKUpdated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostateInt J Radiat Oncol Biol Phys20014993794611240234
   PubMed Web of Science ®Google Scholar
• MiljenkoVPilepichMWinterKAndrogen suppression adjuvant to definitive radiotherapy in prostate carcinoma – long-term results of phase III RTOG 85-31Int J Radiat Oncol Biol Phys2005611285129015817329
   PubMed Web of Science ®Google Scholar
• PilepichMVWinterKRussellAHPhase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation before and during radiotherapy in locally advanced carcinoma of the prostateProc Am Soc Clin Oncol199817308a
   Google Scholar
• MiljenkoVPilepichMVWinterKPhase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostateInt J Radiat Oncol Biol Phys2001501243125211483335
   PubMed Web of Science ®Google Scholar
• HorwitzEMWinterKHanksGESubset analysis of RTOG 85-13 and 86-10 indicates an advantage for long-term vs short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer therapy with radiation therapyInt J Radiat Oncol Biol Phys20014994795611240235
   PubMed Web of Science ®Google Scholar
• BollaMGonzalezDWardePImproved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelinN Engl J Med19973372953009233866
   PubMed Web of Science ®Google Scholar
• LaverdiereJGomezJLCusanLBeneficial effect of combined therapy administered prior and following external beam radiation therapy in localized prostate cancerInt J Radiat Biol Phys199737247252
   PubMed Web of Science ®Google Scholar
• HanksGeraldEPajakKPhase III trial of longterm adjuvant adrogen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02J Clin Oncol2003213972397814581419
   PubMed Web of Science ®Google Scholar
• TyrellCJPayneHSeeWABicalutamide (‘Casodex’) 150 mg as adjuvant to radiotherapy in patients with localized or locally advanced prostate cancer: results from the randomized Early Prostate Cancer ProgrammeRadiother Oncol20057641016145740
   PubMed Web of Science ®Google Scholar
• BollaMde ReijkeTMTienhovenGVDuration of androgen suppression in the treatment of prostate cancerN Engl J Med20093602516252719516032
   PubMed Web of Science ®Google Scholar
• DiBlasioCJMalcolmJBDerweeshIHPatterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancerBJU Int2008102394318294309
   PubMed Web of Science ®Google Scholar
• PotoskyALReeveBBCleggLXQuality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapyJ Natl Cancer Inst20029443043711904315
   PubMedGoogle Scholar
• FowlerFJJrMcNaughton CollinsMWalker CorkeryEElliottDBBarryMJThe impact of androgen deprivation on quality of life after radical prostatectomy for prostate carcinomaCancer20029528729512124828
   PubMed Web of Science ®Google Scholar
• GreenHJPakenhamKIHeadleyBCQuality of life compared during pharmacological treatments and clinical monitoring for nonlocalized prostate cancer: a randomized controlled trialBJU Int20049397597915142146
   PubMed Web of Science ®Google Scholar
• DacalKSereikaSMGreenspanSLQuality of life in prostate cancer patients taking androgen deprivation therapyJ Am Geriatr Soc200654859016420202
   PubMed Web of Science ®Google Scholar
• GreenHJPakenhamKIHeadleyBCGardinerRACoping and health-related quality of life in men with prostate cancer randomly assigned to hormonal medication or close monitoringPsychooncology20021140141412228873
   PubMed Web of Science ®Google Scholar
• SpetzACHammarMLindbergBSpangbergAVarenhorstEScandinavian Prostatic Cancer Group-5 Trial StudyProspective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostateJ Urol200116651752011458057
   PubMed Web of Science ®Google Scholar
• HolzbeierleinJMManaging complications of androgen deprivation therapy for prostate cancerUrol Clin North Am20063318119016631456
   PubMed Web of Science ®Google Scholar
• DerweeshIHDiblasioCJKincadeMCRisk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancerBJU Int20071001060106517868420
   PubMed Web of Science ®Google Scholar
• KeatingNLO’MalleyAJSmithMRDiabetes and cardiovascular disease during androgen deprivation therapy for prostate cancerJ Clin Oncol2006244448445616983113
   PubMed Web of Science ®Google Scholar
• Braga-BasariaMDobsASMullerDCMetabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapyJ Clin Oncol2006243979398316921050
   PubMed Web of Science ®Google Scholar
• BasariaSMullerDCCarducciMAEganJDobsASHyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapyCancer200610658158816388523
   PubMed Web of Science ®Google Scholar
• SmithMRLeeHNathanDMInsulin sensitivity during combined androgen blockade for prostate cancerJ Clin Endocrinol Metab2006911305130816434464
   PubMed Web of Science ®Google Scholar
• LookerACOrwollESJohnstonCCJrPrevalence of low femoral bone density in older US adults from NHANES IIIJ Bone Miner Res199712176117689383679
   PubMed Web of Science ®Google Scholar
• SmithMRAndrogen deprivation therapy for prostate cancer: new concepts and concernsCurr Opin Endocrinol Diabetes Obes20071424725417940447
   PubMedGoogle Scholar
• MalcolmJBDerweeshIHKincadeMCOsteoporosis and fractures after androgen deprivation initiation for prostate cancerCan J Urol2007143551355917594745
   PubMedGoogle Scholar
• ShahinianVBKuoYFFreemanJLGoodwinJSRisk of fracture after androgen deprivation for prostate cancerN Engl J Med200535215416415647578
   PubMed Web of Science ®Google Scholar
• SmithMRLeeWCBrandmanJWangQBottemanMPashosCLGonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancerJ Clin Oncol2005237897790316258089
   PubMed Web of Science ®Google Scholar
• MaillefertJFSibiliaJMichelFSaussineCJavierRMTavernierCBone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinomaJ Urol19991611219122210081873
   PubMed Web of Science ®Google Scholar
• MalcolmJBDiblasioCJWomackJHAssociation of cerebrovascular accident and myocardial infarction with Androgen Deprivation TherapyJ Urol2007177200
   Web of Science ®Google Scholar
• TsaiHKD’AmicoAVSadetskyNChenMHCarrollPRAndrogen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortalityJ Natl Cancer Inst2007991516152417925537
   PubMed Web of Science ®Google Scholar
• LevineGND’AmicoAVBergerPAndrogen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation OncologyCA Cancer J Clin20106019420120124400
   PubMed Web of Science ®Google Scholar